PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.45%
Revenue growth above 1.5x AVGO's 6.52%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
11.88%
Gross profit growth 1.25-1.5x AVGO's 8.76%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
20.05%
EBIT growth 50-75% of AVGO's 36.71%. Martin Whitman would suspect suboptimal resource allocation.
20.81%
Operating income growth at 50-75% of AVGO's 36.71%. Martin Whitman would doubt the firm’s ability to compete efficiently.
21.69%
Net income growth above 1.5x AVGO's 9.32%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
22.86%
EPS growth above 1.5x AVGO's 9.09%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
22.33%
Diluted EPS growth of 22.33% while AVGO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-0.60%
Share reduction while AVGO is at 0.99%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.69%
Reduced diluted shares while AVGO is at 0.68%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.00%
Maintaining or increasing dividends while AVGO cut them. John Neff might see a strong edge in shareholder returns.
87.79%
OCF growth above 1.5x AVGO's 4.61%. David Dodd would confirm a clear edge in underlying cash generation.
100.52%
FCF growth above 1.5x AVGO's 5.58%. David Dodd would verify if the firm’s strategic investments yield superior returns.
61.16%
10Y revenue/share CAGR under 50% of AVGO's 434.54%. Michael Burry would suspect a lasting competitive disadvantage.
38.87%
5Y revenue/share CAGR under 50% of AVGO's 343.33%. Michael Burry would suspect a significant competitive gap or product weakness.
26.13%
3Y revenue/share CAGR under 50% of AVGO's 116.03%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
61.31%
10Y OCF/share CAGR under 50% of AVGO's 1351.20%. Michael Burry would worry about a persistent underperformance in cash creation.
63.85%
Below 50% of AVGO's 678.79%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
33.59%
3Y OCF/share CAGR under 50% of AVGO's 223.95%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
137.49%
Below 50% of AVGO's 474.79%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
87.46%
5Y net income/share CAGR at 75-90% of AVGO's 99.69%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
66.91%
Below 50% of AVGO's 280.16%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
41.50%
Equity/share CAGR of 41.50% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
10.21%
Below 50% of AVGO's 420.76%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
12.58%
Below 50% of AVGO's 292.62%. Michael Burry suspects a serious short-term disadvantage in building book value.
522.75%
Dividend/share CAGR of 522.75% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
191.83%
Below 50% of AVGO's 500.34%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
66.48%
Below 50% of AVGO's 210.49%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
7.28%
AR growth is negative/stable vs. AVGO's 16.59%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-2.00%
Inventory is declining while AVGO stands at 9.15%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.99%
Asset growth above 1.5x AVGO's 0.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.24%
BV/share growth above 1.5x AVGO's 0.62%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
-0.79%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-5.07%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.